Medical Device News Magazine

AdaCore’s QGen Automated Code Generator Helps Develop New Artificial Lung Equipment to Treat Covid Patients in Only6 Months

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Leading provider of software development and verification tools, AdaCore, has joined forces with the Eldorado Institute in Brazil and medical device manufacturer Braile Biomédica to help in the fight against COVID-19.

AdaCore’s code generation and model verification tool software suite, QGen, played an integral part in the development of Braile Biomédica’s new extracorporeal membrane oxygenation (ECMO) device to help COVID-19 sufferers experiencing blood oxygen deficits. Thanks to the technical expertise and dedication of all three organizations, what would have been a two-year development program has been completed in just six months.

AdaCore’s QGen is a qualifiable and tunable code generator for a safe subset of Simulink® and Stateflow® models. The Eldorado Institute had already used the software suite in a cardiac pacemaker pilot project. After using the pilot project to build up a mature understanding of how to use QGen in code generation and verification, they began applying QGen on other projects, including Braile Biomédica’s expedited ECMO device.

The Eldorado Institute (Eldorado) is a private research and technology organization (RTO) based in Brazil. It collaborates with technology companies around Brazil and in other countries to develop new products. Braile Biomédica initially partnered with Eldorado to develop hyperthermic intraperitoneal chemotherapy (HIPEC) equipment. Also known as “hot chemotherapy,” HIPEC is performed after tumors or lesions are removed from the abdominal area.

When the COVID-19 pandemic exploded in Brazil in March 2020, Braile Biomédica redeployed this technology into an ECMO device, designed to help patients battling the virus. The device supports patients with severe lung injuries, keeping the patient alive until the lung recovers and the disease regresses. It consists of a machine and a set of disposable devices, which together perform the circulation and oxygenation of the patient’s blood outside his or her body. QGen is an integral part of the process, delivering clean, readable code and ensuring accurate testing to ensure a high level of reliability and quality performance for the entire time the ECMO is in use.

The ECMO device had to be extremely reliable, regardless of the tight development timeframe. Treatments could last as long as thirty-forty days, during which time the ECMO is responsible for keeping the patient alive. High reliability in such a device is critical to patient survival. The easiest way to assure that is by using model-based systems engineering (MBSE) techniques to design and test the system, and then to generate the code for the target controller hardware directly from the model using an automated code generator, as provided by QGen.

AdaCore QGen Team Lead, JC Bernedo, says: “QGen is a trusted code generator, meaning that the source code it generates is guaranteed to be equivalent to the Simulink simulation environment and therefore directly usable without further manual review. This allows developers of critical systems to streamline their development, testing, and verification processes while providing additional safety guarantees to their customers. We are proud to have helped Braile Biomédica and The Eldorado Institute expedite the development of their life-saving ECMO device.”

Guilherme Fonseca, Manager of Research and Development at The Eldorado Institute adds: “When we were looking for a solution to our design testing and code generation requirements, we found that QGen best matched what we needed. It provided us with the best overall value, thanks to the easily readable generated code, and the guarantee of equivalence of behavior between the generated code and simulation. AdaCore showed us excellent partnership and support throughout the development process. Going forward, whenever we have an opportunity that demands development of high-risk, high-reliability software, we are going to use QGen to verify our model and generate high-reliability code.”

Full case study here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”